Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis

  • Technology appraisal guidance
  • TA386
  • Published: 

Review decision – July 2019

Decision to move the existing guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance TA386; Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis.

We did not identify any new evidence that would change the existing recommendation in TA386. 

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently, TA386 will move to the ‘static list’ of technology appraisals.

Review decision paper

Matrix of stakeholders

This page was last updated: